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Abstract: The relationship involving acid-base imbalance, mineral metabolism and bone health
status has previously been reported but the efficacy of the alkalizing supplementation in targeting
acid overload and preventing bone loss has not yet been fully elucidated. In this randomized,
double-blind, placebo-controlled study, the hypothesis that potassium citrate (K citrate) modifies
bone turnover in women with postmenopausal osteopenia was tested. Three hundred and ten women
were screened; 40 women met the inclusion criteria and were randomly assigned to the treatment
or the placebo group. They were treated with K citrate (30 mEq day−1) or a placebo in addition to
calcium carbonate (500 mg day−1) and vitamin D (400 IU day−1). At baseline and time points of 3 and
6 months, serum indicators of renal function, electrolytes, calciotropic hormones, serum bone turnover
markers (BTMs) (tartrate-resistant acid phosphatase 5b (TRACP5b), carboxy-terminal telopeptide of
type I collagen (CTX), bone alkaline phosphatase (BAP), procollagen type 1 N terminal propeptide
(PINP)), and urine pH, electrolytes, and citrate were measured. The follow-up was completed by
17/20 patients in the “K citrate” group and 18/20 patients in the “placebo” group. At baseline,
90% of the patients exhibited low potassium excretion in 24 h urine samples, and 85% of cases had
at least one urine parameter associated with low-grade acidosis (low pH, low citrate excretion).
After treatment, CTX and BAP decreased significantly in both groups, but subjects with evidence of
low-grade acidosis gained significant benefits from the treatment compared to the placebo. In patients
with low 24h-citrate excretion at baseline, a 30% mean decrease in BAP and CTX was observed at
6 months. A significant reduction was also evident when low citrate (BAP: −25%; CTX: −35%) and
a low pH (BAP: −25%; CTX: −30%) were found in fasting-morning urine. In conclusion, our results
suggested that K citrate supplementation improved the beneficial effects of calcium and vitamin D
in osteopenic women with a documented potassium and citrate deficit, and a metabolic profile
consistent with low-grade acidosis.
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1. Introduction
Bone mass tends to peak around the third decade of life, after which a continuous decline of
0.7% per year is considered to be physiologic. After menopause, however, bone loss is accelerated
and, on average, women lose approximately 5% of trabecular bone and 1.5% of the total bone mass
per year [1]. Postmenopausal estrogen deficiency is considered to be the major cause of accelerated
bone loss [2]. It is associated with an increased rate of bone turnover, with an elevated number of
active bone remodeling units (BRUs) in which the removal of bone by osteoclasts (OCs) prevails
over the formation of bone matrix by osteoblasts (OBs) [3,4]. The imbalance between osteogenesis
and bone resorption leads first to osteopenia and, subsequently, to osteoporosis, both characterized
by decreased bone mineral density (BMD) (T-scores of <−1 and <−2.5, respectively), deterioration
of bone microarchitecture, impairment of bone strength and, ultimately, increased susceptibility
to fracture [5]. According to the “International Osteoporosis Foundation”, it is estimated that
osteoporosis affects 200 million women worldwide, and the lifetime risk of experiencing fragility
fractures to the distal wrist, vertebral body or proximal femur is approximately 30–35% for women
over 50 years of age [6]. Disability due to osteoporotic fractures notably compromises the activities
of daily living (ADL). Actually, the level of self-sufficiency is significantly decreased in 50% of
women with hip fractures, and approximately 20% are candidates for long-term institutionalization [6].
Moreover, the risk of mortality in patients with fractures of the proximal femur is at least double with
respect to an age-matched population [7]. While the highest rate of fractures is found in osteoporotic
women, the absolute number is higher in osteopenic women due to the number of subjects with this
condition [8]. This suggests that the risk profile of osteopenic women should be carefully evaluated
shortly after menopause in order to identify the multiple factors which may promote bone frailty and
make a “fracture event” more likely [8,9]. The risk of fracture is commonly evaluated by algorithms,
i.e., the FRAX® tool (https://www.sheffield.ac.uk/FRAX/) [10]. However, the evaluation of additional
risk factors could be useful for identifying osteopenic women who may benefit from specific measures
aimed at preventing bone loss.
Among the risk factors, it is well recognized that the proper intake of calcium and vitamin D plays
an important role in preserving bone mass, but there are also other factors which seem to influence
BMD [2]. For instance, adverse metabolic conditions (e.g., a high acid load) may increase the rate of
bone loss and favor the onset and progression of osteopenia [11]. In fact, the skeleton is an alkaline
reservoir which plays a pivotal role in maintaining the acid-base balance since it is able to modify
the composition of the bone mineral matrix by acting as an “ion exchange column” and recovering
alkali groups from hydroxyapatite in order to neutralize the proton excess [12]. In addition, it has been
proven that acidosis directly influences the OC and OB activity. In fact, while OCs are virtually inactive
at a pH of 7.4, the resorbing properties are stimulated when the pH drops below 6.9. The acidic milieu
also significantly inhibits the osteogenic function, including the production of extracellular matrix,
the activity of alkaline phosphatase, and the formation of trabecular bone [12].
A chronic subclinical inflammatory status [13], diets rich in salt and meat protein [14] as well
as decreased renal function due to aging [15] are some of the conditions which determine low-grade
acidosis. This is a metabolic condition in which the high acid load may exceed the physiological
neutralization capacity while maintaining the blood pH within the normal range (7.35–7.45), albeit
at values close to the lower limit [14]. While the nutritional hypothesis has been amended in
systematic reviews and meta-analyses [11,16,17], the relationship between renal function, and the risk
of osteoporosis or hip fracture has been confirmed in many studies. Recent findings have demonstrated
that increased acid excretion [18], dysregulation of calcium homeostasis [19] and a decrease in urinary
citrate [20–22] are recognizable in patients who exhibit osteopenia/osteoporosis and high bone
turnover, thus, suggesting that urinary metabolic profiling may have significant implications for
monitoring bone health status.
Since low pH is a risk factor which accelerates bone loss, some authors have proposed using
strategies capable of opposing the acid overload as measures for preventing osteopenia progression
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or for supporting the treatment of osteoporosis. Proton pump inhibitors could be an effective
strategy since these drugs have been designed specifically for counteracting proton excess [23].
However, they are not recommended for long-term treatment as they seem to enhance fracture risk by
inhibiting calcium absorption [24]. Alternatively, alkalizing supplements have been proposed as a valid
tool for limiting the adverse effects of acidosis and delaying bone loss [25]. For instance, potassium
citrate (K citrate) is an alkaline compound used to increase urinary pH and prevent the precipitation
of solutes in the urinary tract [26]. Previous in vitro studies demonstrated that K citrate is capable
of preventing the adverse biological effects which a low extracellular pH induces on human bone
cells [27]. A recent meta-analysis has shown that the daily administration of alkalizing supplements,
including K citrate, for a time span ranging from 6 months to 2 years, led to a significant reduction in
acid and calcium excretion, and a reduction in bone resorption, thus, suggesting a potential benefit
to bone health [25]. However, the authors highlighted the significant heterogeneity of the studies,
as the dosages, duration of treatment, patient inclusion criteria, primary outcomes and endpoints
were very different. As a consequence, valid evidence in support of beginning the use of K citrate
supplementation is still lacking.
To test the hypothesis that the daily administration of K citrate would be able to modify
serum markers of bone resorption and formation, we performed a six-month prospective study in
a homogeneous cohort of women with postmenopausal osteopenia. Moreover, laboratory parameters
which could be useful in recognizing the osteopenic women who may benefit from the alkalizing
treatment were searched for.
2. Materials and Methods
2.1. Study Design and Participants
A randomized, double-blind, placebo-controlled, parallel-group study, with balanced
randomization (1:1) was designed. The study was approved by the local research committee and
registered at Clinical Trial Gov (ID: NCT02731820). The participants were recruited from a cohort
of postmenopausal women treated at the Radiodiagnostic Unit of Rizzoli Orthopedic Institute (IOR)
from January 2016 to June 2017; periodic measurements of lumbar (at the L2–L4 level) and femoral
BMD were carried out using dual-energy X-ray absorptiometry (DXA) (Discovery DXA System,
Hologic Inc., Bedford, MA, USA). Written informed consent was obtained from all participants.
A code was assigned to each woman at the beginning of the trial which was used to track the data
throughout the study. The inclusion criteria were women with osteopenia (T-score <−1 and >−2.5)
and more than 5 years post-menopause. The risk of fracture was evaluated by using the FRAX®
tool [10] based on an algorithm that takes into account demographic characteristics, medical history,
some clinical risk factors as well as bone mineral density (BMD) at the femoral neck. The exclusion
criteria were risk of fracture (FRAX: >20 major osteoporotic fractures; >3 hip fractures), hyperkalemia,
renal insufficiency, urolithiasis, use of therapies influencing bone metabolism (e.g., corticosteroids,
aromatase inhibitors and estrogens), use of drugs (such as diuretics and proton pump inhibitors),
calcium and potassium supplements, vitamin D, current or recent (less than three years prior to
the start of the study) use of bisphosphonates, gastrointestinal disorders which hamper nutrient
absorption, and mental or psychiatric disorders which precluded the possibility of correctly adhering
to the protocol. All the women were interviewed regarding food habits; they followed their usual
diet throughout the duration of the study. Participants were assigned to the treatment or the placebo
group using a randomization sequence created by independent personnel (IOR pharmacy) using a free
online tool (http://randomization.com) and were stratified with a 1:1 allocation using a random block
size of 4.
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2.2. Supplements
The K citrate and the placebo were kindly provided by a manufacturer (Biohealth, Turin, Italy).
They were in tablet form, identical in appearance, and were packaged in bottles which were rendered
anonymous (A and B) until the end of the study. The products were stored at the IOR pharmacy and
dispensed according to the computer-generated randomization list. Each woman received the supplements
in the corresponding prepacked bottle. Both the subjects and the investigators who followed up the
participants were blinded to group assignment. All subjects had daily supplementation with vitamin D3
cholecalciferol (400 IU day−1) and calcium carbonate (500 mg day−1). The participants assigned to the
experimental group received 30 mEq K citrate daily in two tablets for oral administration; those assigned to
the placebo group received the same quantity of tablets containing only the excipients. The participants
had clinic visits at the time of randomization (baseline), and at 3 and 6 months. At each time point,
they underwent blood and urine evaluations. The laboratory staff performing the assays was unaware of
the source of the samples which were identified by numeric codes.
2.3. Blood Analyses
Fasting venous blood samples were collected and analyzed for creatinine, sodium, potassium, total
calcium, inorganic phosphate, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D. These analytes
were measured by routine methods.
2.4. Urine Analyses
Urine samples were collected using a standardized protocol (Lithotest®, Biohealth, Turin, Italy),
and the metabolic profile was examined in an external certified lab (Lithocenter, Turin, Italy).
Briefly, during collection, 24-hour (24 h) urine was aliquoted into two fractions to which 10 mL
hydrochloric acid (to prevent calcium/phosphate precipitation) and 1 mL Hibitane (to prevent
bacterial contamination) were added. The acidified aliquot was used to quantify calcium (Ca), citrate,
magnesium (Mg), oxalate, phosphate (PO4) and sulphate (SO4); the Hibitane aliquot was tested for
ammonium, chloride (Cl), creatinine, pH, potassium (K), sodium (Na), urea, and urate. In addition,
a sample of fasting-morning urine was collected within 2 h after the 24 h collection ended, and was
analyzed for citrate, calcium, urate (all expressed as creatinine ratios) and pH. Reference values were
established on the basis of the assessment of mineral metabolic profile to evaluate the lithogenic
risk [28–30]. The renal acid load was determined by calculating the 24 h urinary “potential renal acid
load” (uPRAL) as follows [31]:
[Cl (mmol day−1) + SO4 (mmol day−1) × 2 + PO4 (mmol day−1) × 1.8] − [Na (mmol
day−1) + K (mmol day−1) + Mg (mmol day−1) × 2 + Ca (mmol day−1) × 2]
2.5. Immunoenzymatic Assay of BTM
The serum level of the bone turnover markers (BTMs) was evaluated at baseline and after 3 and
6 months of treatment. The BTM assay was carried out by following the recommended actions to
minimize the pre-analytical variability [32]. The blood samples were collected after overnight fasting
(between 08:00 and 10:00 a.m.), centrifuged within 2 h from collection, at 1000 g min−1 for 15 min and at
room temperature. The serum was transferred into cryotubes (0.5 mL of serum per cryotube) and frozen
at −80 ◦C, within 1 h after centrifugation, until testing. The BTM serum levels were measured using
commercially available reagents based on a sandwich enzyme immunoassay technique, following the
manufacturer’s protocols, with each sample tested in duplicate. The selected BTMs were related to
(i) the number of osteoclasts (tartrate-resistant acid phosphatase 5b; TRACP5b); (ii) osteoblast function
(bone alkaline phosphatase; BAP); (iii) type I collagen degradation (carboxy-terminal telopeptide;
CTX); (iv) type I collagen precursor (procollagen type 1 N terminal propeptide; PINP). Source and
technical notes of reagents used in this study are shown in Table S1.
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2.6. Calculations and Statistical Analysis
All calculations and analyses were carried out using StatView 5.01 for Windows (SAS Institute
Inc., Cary, NC, USA) and MedCalc Statistical Software version 18.2.1 (MedCalc Software bvba,
Ostend, Belgium). The sample size calculation was based on a previous randomized clinical trial (RCT)
aimed to evaluate the effect of K citrate on calcium metabolism and BTM in a cohort of individuals
(males and females, age >55 years) treated for 6 months [33]. The present RCT was powered considering
a Type I error (α) = 0.05 (two-sided), and Type II error (β) = 0.20 (power is 80%). Fifteen patients
per group were sufficient, but the expected proportion of dropouts was 20%; therefore, as a precaution,
20 women in each group were recruited. Quantitative data were expressed as the arithmetic mean plus
or minus the standard error of the mean (mean ± SEM). The D’Agostino-Pearson method was used to
test the normality assumption of continuous variables, and a log transformation was applied when
the data distribution was non-normal. The data analysis was carried out following intention-to-treat
principles. All follow-up parameters were analyzed using a “last value carried forward” approach
under the intention-to-treat principle in order to address missing data [34]. The effect of K citrate on
BTMs and blood/urine analytes was evaluated by applying the t-test, with comparison within the
groups (paired analysis of the effect of treatment over time), and between the groups (independent
comparison between K citrate and the placebo at the same time point). In order to highlight the
changes over time, the results were expressed in line-graphs as deviations from the value observed
before treatment, i.e.,
[(BTM concentration at time point × BTM concentration at baseline−1) − 1]
Thus, obtaining a baseline value equal to zero. The degree of association between the continuous
variables was calculated by measuring the Pearson correlation coefficient. Differences and correlations
were considered to be statistically significant when the p value was <0.05.
3. Results
3.1. Demographic and Clinical Characteristics of the Participants at Baseline
From January 2016 to June 2017, 310 women with osteopenia and more than 5 years post-menopause
were screened. Forty women met the inclusion criteria and expressed their consent to be enrolled in
the randomized controlled trial (RCT). The flow diagram in Figure 1 shows the numbers of participants
who were randomly assigned to each group, received the intended treatment, and were analyzed for
the primary outcome. Simultaneously, the losses and exclusions after randomization, together with their
reasons, have been displayed [35]. Seventeen out of 20 patients in Group A (K citrate) and 18/20 in Group B
(placebo) completed the study. The dropouts related to the interventions were 1/20 in the K citrate group
(gastritis) and 2/20 in the placebo group (persistent constipation). Two patients decided to discontinue
treatment for personal reasons.
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Figure 1. CONSORT flow diagram.
Adherence to the treatment was 90.3 ± 9% for the K citrate group and 91.2 ± 10% for the placebo
group. All women were interviewed about food habits and they declared to consume a non-vegetarian
diet, with a low to moderate amount of animal protein, while fruits and plant food was more abundant.
The FRAX score did not vary during the follow-up, since relevant events that could influence the
algorithm and modify the risk of fracture were not recorded. At baseline, the demographic and clinical
characteristics of the two groups were comparable, including ge, p stmenopausal years, b dy mass
index (BMI), femur and lumbar T-scores and risk for osteoporotic fractures (Table 1). Similarly,
no significant diffe ences were found i creatinine, sodium, p tassium, total calcium, inorganic
phosphate, magnesium, parathyroid hormone and 1,25-dihydroxyvitamin (Table 2). Regarding the
urinary metabolic profile, the only difference at baseline was the excretion of oxalate in the 24 h urine
(Table 3). However, oxalate excretion was not a target variable of the present study. The circulating
levels of BTMs at baseline were comparable and no significant difference between the groups was
observed (Table 4).
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Table 1. Demographic characteristics of the patients analyzed 1.
K Citrate (n = 20) Placebo (n = 20)
Age 60.8 ± 1.0 (52.0–69.0; 62.0) 58.2 ± 1.1 (48.0–70.0; 57.0)
Years post-menopause 11.5 ± 1.4 (5.0–31.0; 9.0) 8.3 ± 0.9 (5.0–20.0; 7.5)
BMI (kg m−2) 23.7 ± 1.0 (18.7–37.0; 22.7) 22.9 ± 0.8 (18.3–31.2; 21.8)
T-score
Femoral neck
L2–L4
−1.6 ± 0.1 (−2.4 to −0.6; −1.7)
−1.7 ± 0.1 (−2.3 to −0.6; −1.9)
−1.7 ± 0.1 (−2.4 to −0.5; −1.8)
−1.5 ± 0.1 (−2.4 to − 0.1; −1.5)
FRAX
Major osteoporotic risk
Minor osteoporotic risk
5.7 ± 0.8 (2.2–19.0; 4.9)
1.1 ± 0.2 (0–3.1; 0.9)
4.8 ± 0.3 (2.4–8.6; 4.7)
1.0 ± 0.1 (0.1–1.9; 1.0)
1 Data expressed as mean plus or minus the standard error of the mean (mean ± SEM) (min–max; median).
Table 2. Chemistry and hormones levels in serum 1.
Analyte (Unit) Reference Values Baseline 3 Months 6 Months
K Citrate Placebo K Citrate Placebo K Citrate Placebo
Creatinine
(mg dL−1) 0.5–1.2 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 0.7 ± 0.0
Calcium
(mg dL−1) 8.6–10.5 9.6 ± 0.1 9.6 ± 0.1 9.5 ± 0.1 9.6 ± 0.1 9.6 ± 0.1 9.7 ± 0.1
Phosphorus
(mg dL−1) 2.5–4.5 3.6 ± 0.1 3.7 ± 0.1 3.7 ± 0.1 3.8 ± 0.1 3.7 ± 0.1 3.8 ± 0.1
Magnesium
(mg dL−1) 1.6–2.6 2.2 ± 0.0 2.1 ± 0.0 2.2 ± 0.0 2.1 ± 0.0 2.2 ± 0.0 2.2 ± 0.0
Sodium
(mg dL−1) 136.0–145.0 142.2 ± 0.5 142.3 ± 0.4 141.2 ± 0.5 141.4 ± 0.5 140.1 ± 0.6 140.6 ± 0.5
Potassium
(mg dl−1) 3.5–5.3 4.5 ± 0.1 4.5 ± 0.1 4.5 ± 0.1 4.4 ± 0.1 4.4 ± 0.1 4.4 ± 0.1
PTH
(pg mL−1) 12.0–88.0 46.5 ± 3.9 47.0 ± 3.3 48.0 ± 4.6 44.2 ± 2.6 44.2 ± 4.9 47.0 ± 4.3
25OH Vitamin D3
(ng mL−1)
<20 failure
20–100 sufficiency
>100 potential
toxicity
31.6 ± 2.3 32.1 ± 1.6 31.0 ± 2.4 34.1 ± 1.9 32.1 ± 1.9 34.9 ± 1.3
1 Data expressed as mean ± SEM; p value for t tests (unpaired comparison) were not significant.
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Table 3. Metabolic profile of the participants evaluated using 24 h and fasting-morning urine samples 1.
Analyte (Unit) ReferenceValues Baseline 3 Months 6 Months
K Citrate Placebo K Citrate Placebo K Citrate Placebo
24 h urine
Diuresis (mL) 1724.0 ± 155.0 1702.0 ± 150.0 1763.0 ± 181.0 1721.0 ± 163.0 1899.0 ± 179.0 1853.0 ± 192.0
pH 5.5–7 6.1 ± 0.1 6.0 ± 0.2 6.5 ± 0.2 6.3 ± 0.1 6.6 ± 0.1 6.2 ± 0.1 a
Creatinine (g day−1) 1.3–1.8 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Citrate (mmol day−1) >3.3 3.0 ± 0.4 3.5 ± 0.4 4.0 ± 0.5 3.2 ± 0.3 4.0 ± 0.4 3.2 ± 0.3
Citrate/Creatinine (mol mol−1) >0.3 0.4 ± 0.1 0.4 ± 0.0 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.4 ± 0.0 a
Potassium (mEq day−1) 50–100 28.6 ± 3.4 30.0 ± 2.9 43.0 ± 10.6 28.5 ± 6.6 46.6 ± 4.4 35.4 ± 3.4 a
Calcium (mg day−1) <200 117.4 ± 16.3 128.7 ± 12.4 124.4 ± 18.3 123.2 ± 13.4 142.8 ± 17.8 140.9 ± 15.5
Calcium/Creatinine (mg mg−1) 0.02–0.2 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Oxalate (mmol day−1) <0.5 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
Oxalate/Creatinine (mmol mol−1) <50 48.9 ± 3.1 35.2 ± 2.7 b 43.0 ± 4.1 40.8 ± 4.5 33.8 ± 1.9 33.9 ± 2.9
Ammonium (mmol day−1) 20–50 20.7 ± 1.0 21.2 ± 0.8 23.3 ± 2.0 20.5 ± 0.7 23.2 ± 1.1 22.1 ± 1.1
Chloride (mEq day−1) 140–240 121.0 ± 11.4 124.1 ± 6.6 180.8 ± 7.2 126.3 ± 9.1 100.9 ± 8.3 110.5 ± 9.8
Magnesium (mg day−1) >50 58.2 ± 5.7 59.1 ± 4.5 61.6 ± 7.6 54.1 ± 5.3 87.5 ± 13.5 70.7 ± 12.9
Phosphate (mmol day−1) <42 13.0 ± 1.2 12.1 ± 1.0 15.1± 3.1 10.0 ± 0.7 12.9 ± 1.7 9.8 ± 0.7
Sodium (mEq day−1) 50–200 101.5 ± 9.8 99.5 ± 5.0 97.9 ± 8.1 111.8 ± 8.5 98.8 ± 8.5 107.2 ± 10.7
Sulphate (mmol day−1) 6–30 11.6 ± 1.0 12.4 ± 0.9 13.8 ± 2.6 11.8 ± 0.7 13.0 ± 1.4 12.3 ± 0.9
Urea (g day−1) 10–35 15.4 ± 0.9 8.5 ± 1.3 17.4 ± 2.0 15.5 ± 0.7 17.2 ± 1.3 15.8 ± 1.3
Uric Acid (mg day−1) <600 417.6 ± 25.0 413.5 ± 20.6 499.8 ± 46.0 389.7 ± 19.0 a 461.4 ± 32.9 395.5 ± 25.1
Fasting-morning urine
pH 5.5–7 6.1 ± 0.2 5.9 ± 0.2 6.3 ± 0.2 6.0 ± 0.2 6.1 ± 0.1 5.6 ± 0.2 a
Creatinine (mg dL−1) n.d.2 76.4 ± 9.6 83.1 ± 12.7 78.4 ± 10.4 63.0 ± 7.7 81.5 ± 11.1 97.82± 15.3
Citrate (mmol L−1) >3.3 2.8 ± 0.3 3.4 ± 0.5 3.4 ± 0.5 2.5 ± 0.3 3.5 ± 0.5 3.3 ± 0.5
Citrate/Creatinine (mol mol−1) >0.3 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.1 0.40 ± 0.04 a
Calcium/Creatinine (mg mg−1) 0.02–0.2 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.12 ± 0.02
Uric Acid (mg dL−1) n.d. 2 36.7 ± 3.3 37.0 ± 4.0 39.3 ± 4.7 29.0 ± 3.0 35.6 ± 4.5 36.0 ± 4.0
1 Data expressed as mean ± SEM. 2 Not determined. a p < 0.05 and b is p < 0.005 (t test for unpaired comparison).
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Table 4. Serum levels of bone turnover markers 1.
Marker Baseline 3 Months 6 Months
K Citrate Placebo K Citrate Placebo K Citrate Placebo
Carboxy-terminal
telopeptide of type I collagen
(CTX) (µg L−1)
0.64 ± 0.08 0.64 ± 0.05 0.63 ± 0.08 0.56 ± 0.05 0.53 ± 0.08 0.54 ± 0.06
Bone alkaline phosphatase
(BAP) (µg L−1) 21.89 ± 1.67 20.36 ± 1.17 19.81 ± 1.67 18.27 ± 1.00 16.83 ± 1.37 15.79 ± 1.09
Procollagen type 1 N
terminal propeptide
(PINP) (pg L−1)
17.45 ± 1.48 18.82 ± 1.73 16.24 ± 1.60 18.39 ± 1.75 14.9 7 ± 1.51 16.77 ± 1.89
Tartrate-resistant acid
phosphatase 5b
(TRACP5b) (U L−1)
2.35 ± 0.20 2.64 ± 0.22 2.79 ± 0.27 2.85 ± 0.22 2.69 ± 0.29 2.25 ± 0.14
1 Data expressed as mean ± SEM; p value for t tests (unpaired comparison) were not significant.
3.2. K Citrate Supplementation and Changes in Urinary Parameters
The urine metabolic profile was interpreted on the basis of the reference values used to assess
the mineral metabolism [19–21,36]. At baseline, it was found that potassium excretion was <50 mEq
in 90% of the 24 h urine samples, and 85% of women exhibited alteration in pH and/or citrate
excretion. In particular, in 24 h urine a low pH (<5.5) was found in 22.5% of cases, a low total citrate
excretion (≤3.3 mmol day−1) in 57.5%, and a low citrate/creatinine ratio (≤0.3 mmol mol−1) in
32.5%. In fasting-morning urine, low pH was observed in 35% of patients, low citrate concentration
(≤3.3 mmol L−1) in 62.5%, and a low ratio citrate/creatinine in 25%. The uPRAL at baseline was
negative in 37/40 patients (range −107.5 to 23). The pH value of fasting-morning urine correlated
directly and significantly with potassium excretion (R = 0.33, p = 0.02) but not with 24 h citrate levels
(R = 0.09; p = 0.58) while a highly significant correlation between potassium and citrate excretion
was found (R = 0.47, p = 0.002). As shown in Table 3, the group treated with K citrate for 6 months
exhibited potassium excretion significantly higher in comparison to the placebo group; pH and citrate
excretion were also significantly more elevated in the experimental group in both fasting-morning and
24 h urine.
In order to minimize individual variability, the changes over time were analyzed, calculating
the deviation from the value observed at baseline (Figure 2). The urinary excretion of citrate
and potassium changed significantly only in the women treated with K citrate, and significant
differences in comparison to the placebo group were already observed at 3 months. An increase
in urine pH was found in both patient groups, even if the effect over time was significant only after
K citrate supplementation.
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Figure 2. Changes in urine (u) parameters according to treatment group. The line-graphs highlight
the changes observed in both fasting-morning urine (A,C,E) and 24 h urine (B,D,F,G). Data are
expressed as mean plus or minus the standard error of the mean (mean ± SEM) of the variations over
time calculated in each subject as [(concentration at time point × concentration at baseline−1) − 1],
with the baseline = 0. Symbols indicate the statistically significant differences over time (paired t test;
* = p < 0.05 vs. Baseline); the symbol in square brackets indicates a statistically significant difference
between groups at the time point highlighted by the arrow (unpaired t test; * = p < 0.05).
3.3. K Citrate Supplementation and Changes in BTM
The serum levels of the BTMs are shown in Table 4, but no significant difference between K citrate
and the placebo was found at baseline and the following time points. Patient-by-patient analysis
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showed that CTX and BAP decreased significantly in both groups (Figure 3), thus, suggesting that
K citrate supplementation does not improve the beneficial effects of treatment with calcium and
vitamin D. Changes in the PINP levels were largely variable while, unexpectedly, TRACP5b, a marker
related to OC number and activity, tended to increase after treatment with K citrate.
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bone alkaline phosphatase (BAP) (A), carboxy-terminal telopeptide of type I collagen (CTX) (B),
procollagen type 1 N terminal propeptide (PINP) (C) and tartrate-resistant acid phosphatase 5b
(TR CP5b) ( ) are expressed as ean SE of the changes calculated in each subject as [(BT
concentration at the ti e point × BTM concentration at baseline−1) − 1] × 100, where the baseline
is 0. Symbols indicate the statistically significant values obtained from the paired t test. K citrate
group: * = p < 0.05 vs. Baseline; ** = p < 0.005 vs. Baseline; † = p < 0.05 vs. 3 months. Placebo group:
§ = p < 0.05 vs. Baseline; §§ = p < 0.005 vs. Baseline; ∇∇ = p < 0.005 vs. 3 months.
In order to explore the effects of K citrate more in depth, patients who exhibited low urine
pH and/or low citrate excretion before treatment were considered separately, while there was no
need to identify those who had low potassium excretion since the defect was present in almost all
patients. Interestingly, in subgroups there is a benefit from K citrate supplementation compared to
the entire case series (Figures 4 and 5). In particular, women with a low citrate excretion in 24 h urine
gained benefits from the experimental treatment, resulting in a 30% mean decrease in BAP and CTX
at 6 months. A significant reduction was also evident in subjects with alterations in fasting-morning
urine, i.e., low citrate excretion (BAP: −25%; CTX: −35%) and low pH (BAP: −25%; CTX: −30%).
In particular, the changes induced by K citrate on CTX were more evident from three to six months,
and statistically significant differences were detectable in subgroups with low pH and low citrate
excretion before treatment (Figure 6A). The differences were more pronounced when the osteopenic
women who exhibited at least one of the above defects were considered in a separate subgroup.
The changes in BAP in the last three-month period were significantly different only in subjects with
a low pH in fasting-morning urine (Figure 6B). Interestingly, PINP levels increased in the patients
with low pH and low citrate excretion who were treated with K citrate while they decreased in the
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placebo group; however, the high variability of the data did not allow pointing out the significant
differences (Figure 6C). No notable results were found for TRACP5b (data not shown). Concerning the
relationship between urine parameters and BTMs, it was found that PINP correlated significantly with
24 h citrate excretion in the entire population (R = 0.24, p = 0.003) and with pH values in the subgroup
with low pH in fasting-morning urine (R = 0.31; p = 0.003).
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Figure 4. BAP changes (%) in the subgroups of patients with signs of low-grade acidosis at baseline. The BAP
changes were analyzed in women who exhibited low urinary (u) pH in fasting-morning urine (A: n = 14),
and low citrate excretion in both fasting-morning urine (B: n = 25) and 24 h urine (C: n = 23; D: n = 13).
Data are expressed as mean± SEM of the BAP change calculated in each subject as described in Figure 3.
The symbols indicate the statistically significant values obtained with the paired t test. K citrate group:
* = p < 0.05 vs. Baseline; ** = p < 0.005 vs. Baseline; † = p < 0.05 vs. 3 months; †† = p < 0.005 vs. 3 months.
Placebo group: § = p< 0.05 vs. Baseline;∇ = p < 0.05 vs. 3 months.
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The CTX changes were analyzed in the women who exhibited low urinary (u) pH in fasting-morning
urine (A: n = 14), and low citrate excretion in both fasting-morning urine (B: n = 25) and 24 h urine
(C: n = 23; D: n = 13). Data are expressed as mean ± SEM of the CTX change calculated in each subject
as described in Figure 3. The symbols indicate the statistically significant values obtained with the
paired t test. K citrate group: * = p < 0.05 vs. Baseline; † = p < 0.05 vs. 3 months. Placebo group:
§ = p < 0.05 vs. Baseline; ∇ = p < 0.05 vs. 3 months.
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Figure 6. BTM changes in the last three-month period of treatment. Data are expressed as mean± SEM of the
changes calculated in each subject as [(BTM concentration at 6 months× BTM concentration at 3 months−1)
− 1]× 100, where the 3-month value is 0. The bars represent the variation in CTX (A), BAP (B), and PINP (C)
in all patients and subgroups who completed the follow-up. All patients: n = 35. Number of patients with
altered parameters in fasting-morning urine: n = 13, pH <5.5; n = 20, citrate <3.3 mol L−1; n = 32, low citrate
and/or pH. Number of patients with altered parameters in 24 h urine: n = 20, citrate <3.3 mol day−1; n = 11,
citrate/creatinine <0.3 mol mol−1; n = 32, citrate and/or pH. The significant differences between K citrate
and the placebo are highlighted by p values < 0.05 over the bars.
4. Discussion
The relationship involving acid-base disequilibrium, mineral metabolism and bone health status
has previously been reported [15,17–21]; however, the benefits of targeting the acid overload to prevent
bone loss have not yet been established and, at present, the indications for alkalizing supplementation
have to be fully elucidated [25]. This study evaluated whether K citrate supplementation influenced
bone turnover by modifying the serum markers, as would be expected by treatments which
oppose bone loss progression. To highlight the conditions in which dietary supplements could
be recommended, particular attention was paid to the metabolic features of the patients who gained
major benefits in terms of BTM changes.
The mineral metabolic profile of patients was delineated by testing urine parameters which,
in previous reports, were seen to have significant implications for monitoring bone health status [20–22].
The present study found that potassium and citrate excretion was below the threshold value in
a considerable proportion of subjects, and, in a smaller group, even low urine pH was found, especially
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in fasting-morning urine. These alterations were consistent with low-grade metabolic acidosis which
promoted bone loss and favored precipitation of the calcium salts [22,37,38].
While it was expected that daily supplementation with K citrate would be able to normalize the
urine defects, favorable results on BTM serum levels were more uncertain since the benefits of this
supplementation in preventing bone loss are still unclear.
By analyzing the entire case series, the present study did not observe differences between the
experimental and the placebo group, indicating that, in order to prevent bone loss progression, it was
not worth using K citrate indiscriminately in all osteopenic women since it did not add anything to the
benefits induced by calcium and vitamin D supplements.
Previous randomized clinical trials have shown that K citrate is able to reduce circulating BTM
levels over time [29,33,39–45], but the results were not homogeneous and significant differences
between experimental treatment and a placebo have been found in only a few studies and for a limited
number of markers [33,42–44]. The heterogeneity of the above results mainly depended on marked
differences in study design and inclusion criteria of study populations, leading to the hypothesis that
K citrate could be more effective in some subjects while others have no benefits.
In the present study, it was assumed that the effects of the alkaline supplementation with K citrate
on bone turnover would be more significant when the signs of low-grade acidosis were identified before
treatment, i.e., when the specific target was present. The hypothesis was confirmed since the subjects with
low urine pH and/or low citrate excretion were analyzed separately and, interestingly, the decrease in BAP
and CTX was more pronounced after K citrate supplementation compared to calcium and vitamin D alone.
Surprisingly, the BTM changes were similar to those observed after the administration of antiresorptive
drugs while they were unexpected after nonpharmacological treatment. This is a noteworthy result since it
has been recognized that a CTX reduction greater than 30% has been correlated with a significant decrease
in the incidence of osteoporotic fracture incidence [32].
The BTMs selected in this study cover different stages of bone remodeling. PINP reflects the
production of type I collagen by OBs and the highest concentration is found during the proliferative
phase; BAP is mainly expressed during matrix maturation; TRACP5b is related to the OC number
while CTX is indicative of their activity [46]. In general, BTM levels reflect the increased BRU activity
and correlate with the bone loss [32] and, therefore, they are considered a useful tool for assessing the
response to anti-osteoporotic drugs. CTX and PINP are recommended by international committees as
the reference markers for bone resorption and bone formation, respectively [47], while data regarding
the clinical usefulness of BAP and TRACP5b are not always consistent [32]. Both resorption and
formation markers decrease due to the effect of antiresorptive therapy, since the decrease in OC
number and activity leads to a rapid reduction in bone formation by OBs determined by the lack
of coupling factors [32]. Conversely, the use of anabolic agents, e.g., teriparatide, induces a greater
and more rapid increase in bone formation markers after 6 months of treatment, especially PINP [48],
but BAP and CTX may also increase over a longer time frame [49]. In this study, it was shown that BAP
and CTX decrease, as expected, after interventions which oppose bone loss progression, but a variable
increase in PINP and TRACP5b levels which is more difficult to interpret was also observed.
The above results allowed hypothesizing the dual activity of K citrate, similar to that of strontium
ranelate which reduced bone resorption and increased bone formation [50]. First, alkali supplementation
counteracted the pro-osteoclastogenic effect of the acid-base disequilibrium, thus, mimicking the
pharmacological properties of antiresorptive drugs. Subsequently, when the citrate and potassium levels
were normalized, and the acid-base balance was restored, K citrate could have exerted an anabolic effect,
as suggested by the PINP increase observed in the last three-month period. It can be hypothesized that, if the
activity of bone formation was favored, new OC would also be formed in order to maintain bone homeostasis,
and the increase in TRACP5b level could have reflected the growing OC number. An increase in PINP
levels after K citrate supplementation has also been described by Jehle et al. [44] while, to our knowledge,
TRACP5b has not been investigated in clinical trials regarding the use of K citrate in osteopenic women.
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The low excretion of potassium and citrate as well as the low pH that we observed in our case
series are signs of low-grade acidosis that could be related to consumption of a high acid-generating
diet since it is recognized that some foods have a higher acid content than others [5,51]. However,
all the women were interviewed regarding food habits; they reported consuming a low/moderate
amount of animal protein and abundant plant food [14,52]. The scarce dietary acid load was proven
by the low daily excretion of some nutritional markers (e.g., creatinine, sulphate, phosphate and urea)
and also confirmed by uPRAL, i.e., the daily net acid excretion without its organic anion component
which had a negative value in more than 90% of the patients [31]. In agreement with the results of
other authors, a direct linkage involving food, low-grade acidosis and osteopenia did not seem to be
plausible in women who consumed a Mediterranean diet [51,53], and there are probably other causes
which played a pivotal role in determining both urine changes and bone weakening [54].
Low potassium excretion was the most frequent urine alteration in the present case series, and it
could have been the earliest change which, in turn, influenced the others. It is known that potassium
depletion decreases intracellular pH and increases H+ secretion into the tubular lumen, causing
hypocitraturia and low urine pH [38]. The present study confirmed that the lower the potassium
excretion, the lower the citrate excretion, and, in turn, the lower the pH value. Since hypokalemia
was never found in the cohort of osteopenic women, the low potassium excretion suggested that the
majority of the subjects had to conserve this alkali element to maintain serum levels in a normal range
and to ensure physiological demand.
Other than low potassium excretion, there were additional reasons which could have explained
the low citraturia in postmenopausal osteopenia. It is well known that estrogen deficiency and aging
are, for the most part, responsible for the depletion of bone mass [3], but they are also involved in the
lowering of citrate excretion [54,55]. True hypocitraturia is usually fixed as lower than 320 mg day−1
(or 1.7 mmol day−1) and is a common finding in recurrent calcium stone formers; however, low citrate
excretion, less severe, has been described in healthy individuals [38], postmenopausal women [55] and
in subjects with a low bone mass [20,21]. Postmenopausal estrogenic decline influences the activation
rate of BRUs, a multicellular whole comprising of OCs and OBs which sequentially resorb old bone
and form new bone. Nevertheless, bone resorption increases by 90% while bone formation increases
by only 45%, thus, resulting in a “net bone loss” [56]. This gap depends on the effects that the lack of
estrogen has on bone cells. On one hand, the activity of the receptor activator of the nuclear factor-κ
B ligand (RANKL), a key factor in OC differentiation, is promoted; on the other hand, the osteogenic
differentiation of mesenchymal stem cells (MSCs) and the survival of mature OBs is suppressed [3].
Since mature OBs are highly specialized cells capable of synthesizing citrate which is necessary
for the stability of hydroxyapatite nanocrystal/collagen complexes, the lower citrate production
due to the impaired OB function accompanies the disruption of the bone microarchitecture [57].
Moreover, OC differentiation and bone resorption are energy-demanding processes, and the citrate
which is synthesized cannot be accumulated because it is essentially utilized through the citric acid
cycle [58,59]. Similarly, the MSC differentiation towards adipocytes requires more citrate as a source
of cytosolic acetyl-CoA for lipid biosynthesis [60]. As a final result, the estrogen deficiency leads to
a “net citrate loss” which could explain the diminished citrate excretion observed in postmenopausal
women. The mechanisms by which estrogenic hormones influence citrate availability are summarized
in Figure 7.
Even though the aims of the present study were reached, there were some limitations. First of
all, the sample size has been calculated empirically on the basis of a previous report that tested the
hypothesis of K citrate superiority without considering the influence of unexpected variables. Instead,
the beneficial effects of K citrate were detected only in osteopenic women with specific metabolic
defects, and, as a consequence, the probability of finding statistically significant results was decreased
since the number of cases within the subgroups was lower [61]. Second, the exclusion of a variety of
possible confounding factors did not allow generalizing the results since the authors did not know
whether concomitant diseases and related treatments could have interfered with the K citrate activity.
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Finally, the short follow-up did not allow the verification as to whether the significant BTM changes
corresponded to an actual increase in BMD.Nutrients 2018, 10, x FOR PEER REVIEW  9 of 20 
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